NCT06233994View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Advanced Hepatocellular Carcinoma
Interventions
BIOLOGICAL

ZG005 Powder for Injection

ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).

DRUG

Donafenib Tosilate Tablets

Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).

BIOLOGICAL

Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).

Trial Locations (1)

Unknown

Changsha Taihe Hospital, Changsha

All Listed Sponsors
lead

Changsha Taihe Hospital

OTHER_GOV

NCT06233994 - A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter